Blood test may predict who benefits from dust mite allergy treatment
NCT ID NCT07436208
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study tested whether two substances in the blood (sST2 and miR-223) can help predict how well patients with dust mite allergies respond to a six-month course of under-the-tongue immunotherapy (SLIT). Fifty-four patients with moderate-to-severe allergic rhinitis received daily SLIT drops. Researchers measured symptom scores and blood markers before and after treatment to see if changes in sST2 and miR-223 levels matched clinical improvement.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sublingual immunotherapy (SLIT) containing house dust mite extracts
- What this could lead to
- If successful, this could lead to a simple blood test to predict which patients will benefit from SLIT for dust mite allergies.
- What could go wrong
- This is a small, early-phase study focused on biomarkers, not treatment effectiveness. The results may not apply to broader populations or lead to a clinical test.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HDM-INDUCED ALLERGIC RHINITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zagazig University outpatients clinics
Zagazig, Egypt